An FDA-approved broad-spectrum curative therapy for multiple major metastatic cancers becomes available before

Question

Six frontier AI models put this at 9% by 28 Sept 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

9% — the median of 6 frontier models, resolving by 2076-09-28.

Answer

Gemini (Google): 7% — Tumor heterogeneity and immune evasion make a single pan-cancer curative regimen medically improbable within 13 years. Pan-tumor approvals like Keytruda for MSI-H exist, but inducing true complete curative remission across distinct metastatic types has zero precedent. FDA approval requires Phase 3 trials demonstrating durable cure, a pipeline requiring at least a decade that currently lacks candidates. Broad mRNA vaccines or universal CAR-T overcoming solid tumor microenvironments by 2035 would be required to clear FDA review by 2040.

Answer

Claude (Anthropic): 5% — A single FDA-approved therapy curing multiple distinct metastatic cancers would defy cancer's deep biological heterogeneity. Cancer encompasses hundreds of molecularly distinct diseases, making one broad-spectrum curative agent biologically implausible even by 2076. Current trends favor personalized combinations (CAR-T, bispecifics, mRNA vaccines) tailored per tumor type, not a single universal cure. A major paradigm shift like reliable pan-cancer neoantigen targeting or universal immune reprogramming would be needed to change this.

Answer

GPT (OpenAI): 67% — The key is whether platform immunotherapies can deliver durable pan-tumor remissions without intolerable toxicity in trials. FDA approval requires sponsors to show substantial evidence in defined indications; a single universal label is less likely than several metastatic labels. Since 2011, checkpoint inhibitors, CAR-T and tumor-agnostic approvals show broadening reach, but durable cures in common solid tumors remain rare. Fifty years permits multiple trial and regulatory cycles; convincing phase III durable-remission data in pancreatic and brain cancers would raise this sharply.

Answer

Grok (xAI): 11% — FDA must green-light a pan-indication metastatic CR therapy by ~2038. No current agent (PD-1, CAR-T, ADC) produces durable CR across lung/breast/CRC/pancreas; pipelines remain indication-specific. Phase-3 oncology programs plus FDA review historically consume 8–12 years after first-in-human, leaving little slack from 2026. A 2027–28 multi-tumor CR signal in a registrational mRNA or cell-therapy trial would raise the odds sharply.

Answer

DeepSeek (DeepSeek): 12% — Metastatic cancer is dozens of genetically distinct diseases; one therapy clearing several of them is a biology problem, not a regulatory one. FDA approvals for metastatic solid tumors are tumor-specific: pembrolizumab's 2017 tissue-agnostic nod covers only MSI-high tumors, roughly 4% of cases. No single agent has ever achieved durable complete remission across multiple major metastatic cancer types; even CAR-T cures only blood cancers. Fifty years of 'war on cancer' produced incremental gains, so the base rate for a pan-cancer cure in any 50-year window is very low.

Answer

Qwen (Alibaba): 7% — A single therapy achieving complete remission across multiple distinct metastatic cancers is a fundamentally different bar than any current pipeline. No therapy in clinical trials today shows curative intent across >3 histologically distinct metastatic cancers; even checkpoint inhibitors work in subsets, not broadly. FDA approval requires phase III data showing durable complete remission in multiple cancer types—a regulatory path that alone takes 8-12 years from first-in-human, and… The resolution criterion demands 'broad-spectrum curative' across 'multiple major metastatic cancers,' which is qualitatively beyond incremental progress; even by 2040…

An FDA-approved broad-spectrum curative therapy for multiple major metastatic cancers becomes available before 2040.

What each one said

An FDA-approved broad-spectrum curative therapy for multiple major metastatic cancers becomes available before 2040.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.